Calidi Biotherapeutics (CLDI) Total Debt (2022 - 2025)

Calidi Biotherapeutics has reported Total Debt for 4 years, with the latest figure at $200000.0 in Q4 2025.

• On a quarterly basis, Total Debt fell 91.0% year-over-year to $200000.0 in Q4 2025; TTM through Dec 2025 was $200000.0, a 91.0% decrease from a year earlier, with the FY2025 full-year figure at $200000.0, down 91.0% from the prior year.
• Total Debt was $200000.0 for Q4 2025 at Calidi Biotherapeutics, down from $400000.0 in the prior quarter.
• The five-year high for Total Debt was $500.0 million in Q2 2025, with the low at $200000.0 in Q4 2025.
• Average Total Debt over 4 years is $37.7 million, with a median of $2.1 million recorded in 2023.
• The largest YoY upside for Total Debt was 14140.96% in 2025 against a maximum downside of 91.0% in 2025.
• Over 4 years, Total Debt stood at $3.7 million in 2022, then tumbled by 44.69% to $2.1 million in 2023, then rose by 7.91% to $2.2 million in 2024, then tumbled by 91.0% to $200000.0 in 2025.
• The last three Total Debt figures came in at $200000.0 (Q4 2025), $400000.0 (Q3 2025), and $500.0 million (Q2 2025), per Business Quant data.